The DOI matches its Crossref record; the references it cites are not checked yet.
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression
Open accessAbstract
Background: Major depressive disorder (MDD) is a highly burdensome health condition, for which there are numerous accepted pharmacological and psychological interventions. Adjunctive treatment (augmentation/combination) is recommended for the ~50% of MDD patients who do not adequately respond to first-line treatment. We aimed to evaluate the current evidence for concomitant approaches for people with early-stage treatment-resistant depression (TRD; defined below). Methods: We systematically searched Medline and Institute for Scientific Information Web of Science to identify randomised controlled trials of adjunctive treatment of ⩾10 adults with MDD who had not responded to ⩾1 adequate antidepressant. The cochrane risk of bias (RoB) tool was used to assess study quality. Pre-post treatment meta-analyses were performed, allowing for comparison across heterogeneous study designs independent of comparator interventions. Results: In total, 115 trials investigating 48 treatments were synthesised. The mean intervention duration was 9 weeks (range 5 days to 18 months) with most studies assessed to have low ( n = 57) or moderate ( n = 51) RoB. The highest effect sizes (ESs) were from cognitive behavioural therapy (ES = 1.58, 95% confidence interval (CI): 1.09–2.07), (es)ketamine (ES = 1.48, 95% CI: 1.23–1.73) and risperidone (ES = 1.42, 95% CI: 1.29–1.61). Only aripiprazole and lithium were examined in ⩾10 studies. Pill placebo (ES = 0.89, 95% CI: 0.81–0.98) had a not inconsiderable ES, and only six treatments’ 95% CIs did not overlap with pill placebo’s (aripiprazole, (es)ketamine, mirtazapine, olanzapine, quetiapine and risperidone). We report marked heterogeneity between studies for almost all analyses. Conclusions: Our findings support cautious optimism for several augmentation strategies; although considering the high prevalence of TRD, evidence remains inadequate for each treatment option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Results from a meta- analysis have supported the efficacy of adding mirtazapine or bupropion in persons with 'early- stage' TRD (i.e., non- response to one adequate pharma cological or psychological therapy for depression) 188 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 43 · Cited by 87
Research works printed but not linked: 6
- Fava M, 2007, Psychiatry (Edgmont), 4, 16
- Higgins JPT, 2022, Cochrane Handbook for Systematic Reviews of Interventions
- Lakens D, 2013, Front Psychol, 26, 863
- Suehs BT, 2008, Texas Medication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms
- Thase ME, 1997, J Clin Psychiatry, 58, 23
- World Health Organisation, 2017, Depression and Other Common Mental Disorders: Global Health Estimates
Metadata
- Authors
- Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., Young, A. H., & Strawbridge, R.
- Affiliations
- South London and Maudsley NHS Foundation Trust (GB)
- King's College London (GB)
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
- Corresponding author
- Strawbridge, Rebecca
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-07-21
- Volume
- 37
- Issue
- 3
- Pages
- 268-278
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC10076341
- OpenAlex
- W4286500354
- Cited by
- 87
- References
- 43
- Citations by year
- 2026: 23 · 2025: 19 · 2024: 26 · 2023: 15 · 2022: 4
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- NIHR Maudsley Biomedical Research Centre (n/a)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- treatment-resistant depression, major depressive disorder, adjunctive therapy, antidepressant augmentation, cognitive behavioral therapy, esketamine, risperidone, aripiprazole, lithium, mirtazapine, olanzapine, quetiapine, placebo response
- MeSH terms
- Aripiprazole, Adult, Depression, Major Depressive Disorder, Humans, Ketamine, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. https://app.cochat.ai/papers/10.1177/02698811221104058
- The paper
- Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., Young, A. H., & Strawbridge, R. (2023). Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221104058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

